Risk Stratification for Prevention of Recurrence of Postoperative Crohn's Disease.

Autor:	Cohen-Mekelburg S; Dr Cohen-Mekelburg and Dr Schneider are gastroenterology fellows, Dr Gold is an internal medicine resident, Dr Scherl is a clinical professor and attending physician, and Dr Steinlauf is an assistant professor and attending physician at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York., Schneider Y; Dr Cohen-Mekelburg and Dr Schneider are gastroenterology fellows, Dr Gold is an internal medicine resident, Dr Scherl is a clinical professor and attending physician, and Dr Steinlauf is an assistant professor and attending physician at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York., Gold S; Dr Cohen-Mekelburg and Dr Schneider are gastroenterology fellows, Dr Gold is an internal medicine resident, Dr Scherl is a clinical professor and attending physician, and Dr Steinlauf is an assistant professor and attending physician at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York., Scherl E; Dr Cohen-Mekelburg and Dr Schneider are gastroenterology fellows, Dr Gold is an internal medicine resident, Dr Scherl is a clinical professor and attending physician, and Dr Steinlauf is an assistant professor and attending physician at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York., Steinlauf A; Dr Cohen-Mekelburg and Dr Schneider are gastroenterology fellows, Dr Gold is an internal medicine resident, Dr Scherl is a clinical professor and attending physician, and Dr Steinlauf is an assistant professor and attending physician at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York.
Jazyk:	angličtina
Zdroj:	Gastroenterology & hepatology [Gastroenterol Hepatol (N Y)] 2017 Nov; Vol. 13 (11), pp. 651-658.
Abstrakt:	Although there have been significant advances in medical therapies to treat Crohn's disease, an estimated 50% of patients will require surgery within the first decade of disease duration. Of these patients, a substantial number will develop recurrent symptoms within the first postoperative year. To prevent disease recurrence, many physicians use postoperative prophylactic therapy. Randomized, controlled trials, although limited in number, have demonstrated that a prophylactic postoperative strategy is effective at reducing recurrence (both clinical and endoscopic) in high-risk patients. This article reviews the frequency of and risk factors for postoperative Crohn's disease recurrence and the current evidence in favor of postoperative Crohn's disease management strategies. Future studies must be conducted to establish a gold standard as to who should receive postoperative prophylaxis and which therapies and time course are ideal. Competing Interests: Dr Scherl has received grant/research support from Abbott Laboratories (AbbVie), AstraZeneca, Janssen Research & Development, and Pfizer, and serves as a consultant to AbbVie, Janssen Pharmaceutical, and Takeda Pharmaceuticals. Dr Steinlauf has received honoraria from AbbVie. The other authors have no relevant conflicts of interest to disclose.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu